Table 5

Kaplan–Meier probability of a cardiovascular adverse event by 3 years by subgroups

	N	Placebo (n=1544)	Salmeterol (n=1542)	FP (n=1552)	SFC (n=546)
Age
<55	706	13.2	12.5	13.4	13.4
55–64	1988	20.2	18.8	20.7	17.4
65–74	2706	26.6	24.8	26.9	22.1
≥75	784	39.2	34.9	35.4	32.9
Sex
Male	4684	24.4	23.0	24.0	20.7^*
Female	1500	23.4	21.9	25.3	21.0
Smoking status
Current	2654	22.2	22.0	22.4	20.5
Former	3530	25.8	23.3	25.9	20.9^*
Baseline FEV₁
<30%	945	25.8	32.1	26.7	23.5
30–<50%	3056	25.7	20.7	25.4	23.4
≥50%	2183	21.7	21.7	21.8	16.2^*
Baseline CV treatment
Yes	2530	33.5	30.3	30.4	27.9^*
No	3654	18.3	17.6	20.2	15.4
Prior MI
Yes	419	49.1	54.4	41.0	44.1
No	5762	22.2	20.2	23.3	19.1
Baseline short-acting anticholinergics
Yes	3715	25.2	24.0	25.6	22.0
No	2469	22.7	21.0	22.4	18.9

↵* p<0.05 versus placebo.
CV, cardiovascular; FEV₁, forced expiratory volume in 1 s; FP, fluticasone propionate; MI, myocardial infarction; SFC, salmeterol/fluticasone propionate combination.